CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment

S Bao, M Darvishi, AH Amin, MT Al-Haideri… - Journal of cancer …, 2023 - Springer
CXC chemokine receptor type 4 (CXCR4) is a member of the G protein-coupled receptors
(GPCRs) superfamily and is specific for CXC chemokine ligand 12 (CXCL12, also known as …

Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects

B Ghafoor, SS Masthan, M Hameed, HH Akhtar… - Annals of …, 2024 - Springer
Waldenström macroglobulinemia (WM) is a chronic B-cell lymphoproliferative disorder
characterized by lymphoplasmacytic cell overgrowth in the bone marrow and increased …

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

SP Treon, K Meid, ZR Hunter, CA Flynn… - Blood, The Journal …, 2021 - ashpublications.org
MYD88 and CXCR4 mutations are common in Waldenström macroglobulinemia (WM).
Mutated CXCR4 (CXCR4Mut) impacts BTK-inhibitor response. We conducted a phase 1 trial …

[HTML][HTML] Fatty acid conjugated EPI-X4 derivatives with increased activity and in vivo stability

M Harms, A Haase, A Rodríguez-Alfonso… - Journal of Controlled …, 2024 - Elsevier
Dysregulation of the CXCL12/CXCR4 axis is implicated in autoimmune, inflammatory, and
oncogenic diseases, positioning CXCR4 as a pivotal therapeutic target. We evaluated …

Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists

P Sokkar, M Harms, C Stürzel, A Gilg… - Communications …, 2021 - nature.com
Abstract EPI-X4, a 16-mer fragment of albumin, is a specific endogenous antagonist and
inverse agonist of the CXC-motif-chemokine receptor 4 (CXCR4) and thus a key regulator of …

Advanced EPI-X4 derivatives covalently bind human serum albumin resulting in prolonged plasma stability

A Rodríguez-Alfonso, A Heck, YB Ruiz-Blanco… - International Journal of …, 2022 - mdpi.com
Advanced derivatives of the E ndogenous P eptide I nhibitor of CX CR 4 (EPI-X4) have
shown therapeutic efficacy upon topical administration in animal models of asthma and …

Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability

M Harms, R Fabech Hansson, A Gilg… - Journal of Medicinal …, 2023 - ACS Publications
EPI-X4, a natural peptide CXCR4 antagonist, shows potential for treating inflammation and
cancer, but its short plasma stability limits its clinical application. We aimed to improve the …

Development of a new class of CXCR4-targeting radioligands based on the endogenous antagonist EPI-X4 for oncological applications

RH Gaonkar, YT Schmidt, R Mansi… - Journal of Medicinal …, 2023 - ACS Publications
The peptide fragment of human serum albumin that was identified as an inhibitor of C–X–C
motif chemokine receptor 4 (CXCR4), termed EPI-X4, was investigated as a scaffold for the …

Dimerization of the peptide CXCR4-antagonist on macromolecular and supramolecular protraction arms affords increased potency and enhanced plasma stability

M Harms, RF Hansson, S Carmali… - Bioconjugate …, 2022 - ACS Publications
Peptides are prime drug candidates due to their high specificity of action but are
disadvantaged by low proteolytic stability. Here, we focus on the development of stabilized …

Peptide Bispecifics Inhibiting HIV-1 Infection by an Orthogonal Chemical and Supramolecular Strategy

D Schauenburg, F Zech, AJ Heck… - Bioconjugate …, 2023 - ACS Publications
Viral infections pose a significant threat to human health, and effective antiviral strategies
are urgently needed. Antiviral peptides have emerged as a promising class of therapeutic …